Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Mammary Glands01:12

The Mammary Glands

The female breast is a hemispheric projection of variable size positioned anterior to the pectoralis major and serratus anterior muscles. A fascia layer composed of dense, irregular connective tissue connects it to these muscles.
Each breast features a pigmented projection known as the nipple, through which milk emerges via closely spaced openings of ducts, referred to as lactiferous ducts. Surrounding the nipple is a circular pigmented area of skin named the areola, which appears rough due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Delphi survey to explore core curriculum for training the next-generation of hepatologists<sup>☆</sup>.

JHEP reports : innovation in hepatology·2026
Same author

Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver-Related Outcomes in Multicohorts.

Aging cell·2026
Same author

The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLD.

Clinical and molecular hepatology·2026
Same author

Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.

Clinics in liver disease·2026
Same author

Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.

European journal of haematology·2026

Related Experiment Video

Updated: Jun 21, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Thierry Poynard1,2, Olivier Deckmyn2, Valentina Peta2

  • 1Medical Faculty, Pitié Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.

Biomedicines
|December 30, 2025
PubMed
Summary

A new classification for liver steatosis using MRI-PDFF detects early disease in 26% of adults. This early metabolic dysfunction-associated steatotic liver disease (MASLD) phenotype shows distinct clinical and biological differences from the normal grade.

Keywords:
FibroSureFibroTestNashTest-2PDFFSteatoTest-2UK-Biobankvery early steatosis

More Related Videos

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.4K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.4K

Related Experiment Videos

Last Updated: Jun 21, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.4K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.4K

Area of Science:

  • Hepatology and Metabolic Diseases
  • Advanced Medical Imaging Techniques
  • Population Health and Epidemiology

Background:

  • Current metabolic dysfunction-associated steatotic liver disease (MASLD) definitions using liver biopsy may underestimate low-grade steatosis.
  • Proposed novel classification based on magnetic resonance imaging-proton-density fat fraction (MRI-PDFF) refines early steatosis grading (new-S0, S1A, S1B).

Purpose of the Study:

  • To evaluate the clinical and biological differences between early MRI-PDFF-defined steatosis phenotypes (S1A/S1B) and the new-S0 grade.
  • To assess the prevalence of these new grades in large, diverse population cohorts.

Main Methods:

  • Prevalence assessment of new MRI-PDFF grades in UK Biobank (N=29,252) and type 2 diabetes outpatients (N=286), plus six published databases (N=149,212).
  • Multimodal steatosis assessment using longitudinal MRI-PDFF and liver biopsy data (N=286).
  • Statistical modeling to adjust for phenotypes and overall mortality, controlling for cardiometabolic factors.

Main Results:

  • In UK Biobank, new-S0, S1A, and S1B grades were prevalent in 54%, 26%, and 17% of participants, respectively.
  • Early steatosis grades (S1A/S1B) were significantly associated with triglycerides, BMI, SBP, and HbA1c.
  • Adjusted analysis revealed significantly lower 15-year survival in higher-risk steatosis groups compared to low-risk.

Conclusions:

  • A substantial proportion (26%) of middle-aged adults exhibit early liver steatosis undetectable by current methods.
  • The novel MRI-PDFF classification identifies distinct early steatosis phenotypes with differing clinical and biological characteristics.
  • This refined grading system has implications for understanding MASLD progression and patient risk stratification.